Thomas Cimato
Cardiovascular Disease · Amherst, NYNPI 1497942809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $305 and has fallen 72.6% since, to $84 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 28 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$172
- Edwards Lifesciences$133
- Abiomed$125
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$117
- Impulse Dynamics (USA) Inc.$115
- Merck$99
- plus $127 from 5 others
Across 32 payments — averaging $6354.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$158K
- Edwards Lifesciences$32K
- AstraZeneca$12K
- Impulse Dynamics (USA) Inc.$650
What the payments were for
- Food & beverage$889100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $172 |
| Edwards Lifesciences | 2 | $133 |
| Abiomed | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $117 |
| Impulse Dynamics (USA) Inc. | 4 | $115 |
| Merck | 6 | $99 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Abbott | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$889 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $311,444 |
| EliquisApixaban | 164 | $215,517 |
| EntrestoSacubitril/Valsartan | 134 | $153,583 |
| XareltoRivaroxaban | 53 | $87,789 |
| JardianceEmpagliflozin | 74 | $79,552 |
| FarxigaDapagliflozin Propanediol | 46 | $60,427 |
| Repatha SureclickEvolocumab | 48 | $27,112 |
| BrilintaTicagrelor | 24 | $20,401 |
| Bumetanide | 202 | $8,726 |
| Metoprolol Succinate | 453 | $8,141 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $7,009 |
| Rosuvastatin Calcium | 320 | $5,252 |
| Isosorbide Dinitrate | 26 | $4,994 |
| Atorvastatin Calcium | 271 | $3,729 |
| Carvedilol | 198 | $2,554 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Amherst
- Vijay IyerAmherst$855K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.